About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Inadequately controlled asthma can be very debilitating and costly for patients. The authors emphasize the importance of tracking symptoms, and they recommend a combined strategy in which both patient and claims data are used to identify poor asthma control.
Tom James, MD, and Michael Fine, MD
A patient with multiple-organ failure recovered from septic shock when a low dose of drotrecogin alfa was administered.
Shan Wang, PharmD, Kristina Dabovic, PharmD, and Ruth S. Spector, MD
Antihypertensive treatments include a dual receptor antagonist (PS433540) and a combination of amlodipine plus olmesartan (Azor).
Reuben B. David
Continuing Education Credit
Part 2 of a two-part series summarizes treatments used to prevent migraine, the most common headache complaint in clinical practice. Current prophylactic therapies include selected beta blockers, antidepressants, anticonvulsant agents, NSAIDs, skeletal muscle relaxants, ACE-inhibitors, antipsychotic agents, antihistamines, botulinum, and herbal products.
George DeMaagd, PharmD, BCPS
David Nash, MD, MBA, describes the concept of "total leadership" and its value in helping people become more authentic, integrated, and creative.
David B. Nash, MD, MBA
In part 1 of a two-part article, Matthew Grissinger, RPh, FASCP, discusses widespread misconceptions about formularies among surveyed health care professionals.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the possible passage of a Senate bill that would allow the FDA to approve "near copies" of biotech agents ("biosimilars").
From dronabinol to rosiglitazone, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Combating Non-nucleoside Reverse Transcriptase Inhibitor Resistance with a Focus On Etravirine (Intelence) for HIV-1 Infection
The authors review etravirine (Intelence), a second-generation non-nucleoside reverse transcriptase inhibitor, for HIV-1 infection.
Nathaniel Eraikhuemen, PharmD, Angela M. Thornton, PharmD, Evans Branch III, PharmD, Sandrine T. Huynh, PharmD, and Candace Farley, PharmD